Archive for category Marijuana Health News

Dr. Lester Grinspoon on Medical Marijuana, Past, Present, and Future

From NORML SHOW LIVE #841 (1/20/2012), Harvard Emeritus Associate Professor Dr. Lester Grinspoon joins us via Skype for an exclusive interview. Topics include his friend, Dr. Carl Sagan, the idea of “recreational” vs. “medical” marijuana use, the opinion “all use is medical”, Allen St. Pierre’s “farce” comments on medical marijuana industry, and medical psychedelics.

If you, or someone you know, is suffering and would like to learn more about using marijuana as medicine, please call Roger A. Barnes, MD at 626-344-7596 or visit http://www.thecannabisdoctors.com

Tags: , , , , , , , , , , , , , , ,

Association Between Marijuana Exposure and Pulmonary Function Over 20 Years – JAMA

Abstract

  1. Mark J. Pletcher, MD, MPH;
    English: Common adverse effects of tobacco smo...
  2. Eric Vittinghoff, PhD;
  3. Ravi Kalhan, MD, MS;
  4. Joshua Richman, MD, PhD;
  5. Monika Safford, MD;
  6. Stephen Sidney, MD, MPH;
  7. Feng Lin, MS;
  8. Stefan Kertesz, MD

Context Marijuana smoke contains many of the same constituents as tobacco smoke, but whether it has similar adverse effects on pulmonary function is unclear.

Objective To analyze associations between marijuana (both current and lifetime exposure) and pulmonary function.

Design, Setting, and Participants The Coronary Artery Risk Development in Young Adults (CARDIA) study, a longitudinal study collecting repeated measurements of pulmonary function and smoking over 20 years (March 26, 1985-August 19, 2006) in a cohort of 5115 men and women in 4 US cities. Mixed linear modeling was used to account for individual age-based trajectories of pulmonary function and other covariates including tobacco use, which was analyzed in parallel as a positive control. Lifetime exposure to marijuana joints was expressed in joint-years, with 1 joint-year of exposure equivalent to smoking 365 joints or filled pipe bowls.

Main Outcome Measures Forced expiratory volume in the first second of expiration (FEV1) and forced vital capacity (FVC).

Results Marijuana exposure was nearly as common as tobacco exposure but was mostly light (median, 2-3 episodes per month). Tobacco exposure, both current and lifetime, was linearly associated with lower FEV1 and FVC. In contrast, the association between marijuana exposure and pulmonary function was nonlinear (P < .001): at low levels of exposure, FEV1 increased by 13 mL/joint-year (95% CI, 6.4 to 20; P < .001) and FVC by 20 mL/joint-year (95% CI, 12 to 27; P < .001), but at higher levels of exposure, these associations leveled or even reversed. The slope for FEV1 was −2.2 mL/joint-year (95% CI, −4.6 to 0.3; P = .08) at more than 10 joint-years and −3.2 mL per marijuana smoking episode/mo (95% CI, −5.8 to −0.6; P = .02) at more than 20 episodes/mo. With very heavy marijuana use, the net association with FEV1 was not significantly different from baseline, and the net association with FVC remained significantly greater than baseline (eg, at 20 joint-years, 76 mL [95% CI, 34 to 117]; P < .001).

Conclusion Occasional and low cumulative marijuana use was not associated with adverse effects on pulmonary function.

Originally available at http://jama.ama-assn.org/content/307/2/173

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Doctors, Patients Assess Effectiveness of Medical Marijuana

Transcript

http://www.pbs.org/newshour/bb/health/july-dec11/marijuana_08-23.html

JEFFREY BROWN: And finally tonight: the benefits and limitations of medical marijuana treatments.

Sixteen states have passed laws that allow patients to use the drug to treat side effects of various illnesses. But now some are moving to either limit or repeal those laws. One of them is Montana.

Special correspondent Anna Rau of Montana PBS recently produced a documentary examining the experiences of patients and doctors. This excerpt focuses primarily on what scientists are learning about marijuana’s therapeutic effects.

MEDICAL MARIJUANA USER: I used to be on approximately 14 different prescriptions, and I would still have up to 12 seizures a day. I used to have to take two handfuls of pills. No more.

ANNA RAU, Montana PBS: While this 27-year-old epilepsy patient in Montana is relieved to be taking medical marijuana…

WOMAN: I’m not using it to get any psychological effects off of it. I’m just eating the butter raw with bread.

ANNA RAU: … she’s considerably more anxious about showing her face, and has requested we conceal her identity.

Why do you not want to show your face?

MEDICAL MARIJUANA USER: I am not comfortable showing my face because of all of discrimination that has already happened.

ANNA RAU: She says both she and her husband have lost jobs when she spoke openly about using marijuana to treat her seizures.

Medical marijuana use has been legal in Montana since 2004, when voters there approved an initiative allowing doctors to recommend it to their patients. However, the federal government still classifies the plant as a schedule one drug. That makes it illegal for doctors to prescribe it, and it means state law doesn’t protect patients from federal arrest and prosecution.

MEDICAL MARIJUANA USER: But the fact of the matter is, somebody has to speak up, or nobody will hear these stories.

ANNA RAU: She told us her story in her artist’s studio. Here, she creates much happier works than she did even a few years ago, when her self-portraits plainly showed the toll epilepsy had taken since she was diagnosed at 15.

MEDICAL MARIJUANA USER: I have taken pretty much every anti-epileptic on the market, and some with a little bit more success than others.

ANNA RAU: None of them stopped her seizures, and, by her early 20s, the epilepsy had also spawned depression, anxiety and insomnia. She had to withdraw from college just a few credits short of a fine arts degree. Unable to hold a job, she was bed-bound for years while the epilepsy ruled her life.

MEDICAL MARIJUANA USER: It’s not a life, to live like that.

ANNA RAU: Then she remembered reading stories about the potential of cannabis to treat epileptic seizures, and she desperately wanted to try it, but her home state doesn’t have a medical marijuana law.

MEDICAL MARIJUANA USER: So, I did what I could do. I moved to a state where I could treat it myself.

ANNA RAU: Medical marijuana critic Dr. Eric Voth says the problem is, patients are treating themselves with a plant that’s voter-approved, not FDA-approved.

DR. ERIC VOTH, Institute on Global Drug Policy: So much of the medical excuse movement has come through ballot initiatives and legislative initiatives. And that’s not the way we bring medicines to market. We bring them to market through the FDA and a very careful process of proving safety and efficacy.

ANNA RAU: Dr. Voth is an addiction and pain specialist in Kansas, and he’s also the chairman of the Institute on Global Drug Policy. He says scientific research is the only legitimate route to understanding marijuana’s medical potential, not a hodgepodge of state laws and anecdotal stories.

He says, when patients smoke or ingest marijuana, they are getting a complex and largely unresearched mix of chemicals known as cannabinoids.

DR. ERIC VOTH: If we’re delivering THC, which is the major active ingredient, shouldn’t we be delivering that alone or other cannabinoids alone? But, in fact, what we’re doing is we’re delivering not only one, but 66 cannabinoids. On top of that, were delivering hundreds of contaminants.

ANNA RAU: This epilepsy patient says she’s willing to take the risk, because something in that cornucopia of substances has changed her life.

How did that impact your seizures?

MEDICAL MARIJUANA USER: They started slowing down. I had to build it up in my system. And it wasn’t until I started ingesting it that they really stopped completely.

DR. ERIC VOTH: I’m very suspicious about it because for someone to have been on 14 medications and not solve her problem, and then have this miraculous benefit from one medicine, I just find that suspect.

ANNA RAU: But the potential of marijuana to mitigate epileptic seizures has been recognized by the U.S. Institute of Medicine. The institute has released two reports on the therapeutic potential of cannabis.

The first report, from 1982, found “substantial evidence from animal studies to indicate that cannabinoids are effective in blocking seizures.” Scientists who wrote the 1999 report also found marijuana had anti-seizure effects, but doubted it could be developed into a pharmaceutical-grade epilepsy drug.

However, both reports detailed the promising ability of cannabis to treat pain and disease differently than conventional pharmaceuticals. That’s exactly what scientists at the California Center for Medicinal Cannabis Research found during several placebo-controlled clinical trials.

Dr. Igor Grant is the center’s director, and he says marijuana is not just an anti-nausea drug.

DR. IGOR GRANT, University of California, San Diego: I can say that the cannabinoids are almost certain to be useful in pain, based on the research that we have done, and probably have a place in muscle spasm.

DR. DONALD ABRAMS, University of California, San Francisco: Marijuana contains anti-inflammatory, anti-oxidant and probably anti-cancer compounds in it.

ANNA RAU: Dr. Donald Abrams is an oncology physician who conducted some of the center’s clinical research. He agrees the cannabis plant is a complex mix of substances, but he believes this is a medical benefit, not a detriment.

DR. DONALD ABRAMS: I’m a cancer doctor, and I often suggest to my patients that they consider marijuana for their loss of appetite, nausea, pain, depression and insomnia. It’s one medicine they could use, instead of five.

ANNA RAU: Critics like Dr. Voth are especially skeptical of these kinds of claims. How is it possible that one plant has the potential to impact so many different ailments?

Intriguing answers started appearing in the early ’90s, when researchers pinpointed receptors in the brain and the body that bind with cannabis. Receptors can be described as locks on the surface of a cell, and when the correct key binds with the correct lock, or receptor, it opens the door and delivers messages. Sometimes, the messages are urgent, for example, that the body is feeling pain, or that there’s an invader and the immune system must attack.

Researchers believe cannabinoids can turn down those messages, helping to temper chronic pain and autoimmune disorders. These special receptors are extremely abundant in the brain, but they are also found all over the body and in the major organs, the heart, the liver, kidneys and pancreas.

After finding all these locks that accepted the cannabis key, researchers made the next big discovery: The human body makes its own cannabinoids.

DR. DONALD ABRAMS: We have these circulating chemicals that we produce ourselves that really are very, very similar to the chemicals in the marijuana plant.

DR. PRAKASH NAGARKATTI, University of South Carolina: The only difference is that the cannabinoids that we produce are in such small quantities, and they’re also rapidly degraded, so that, therefore, we are not high all the time.

ANNA RAU: Dr. Prakash Nagarkatti is a professor of pathology and microbiology at the University of South Carolina. He’s one of many scientists in a race to unlock the mysteries of the receptors by using newly created synthetic drugs, instead of tightly restricted whole cannabis.

These synthetics have made research much easier and potentially lucrative. The U.S. patent database shows numerous large pharmaceutical companies have filed recent patents, claiming their cannabinoid receptor drug has the potential to treat almost everything: multiple sclerosis, Alzheimer’s, Parkinson’s, rheumatoid arthritis, Tourette’s, epilepsy, heart disease, obesity, various mental illnesses and the Holy Grail of medicine, a cancer cure.

Dr. Nagarkatti and his team of researchers were one of the first labs to prove a cannabinoid key can seek out a cancerous cell in the immune system, unlock the receptor, and direct the cancer cell to self-destruct.

DR. PRAKASH NAGARKATTI: So, basically, telling the cells basically to commit suicide.

ANNA RAU: Dr. Nagarkatti’s experimental drug was able to eradicate almost 100 percent of the cancer in test tubes. And when they moved on to live mice:

DR. PRAKASH NAGARKATTI: To our surprise, we found that almost 25 to 30 percent of the mice completely rejected the tumor. They were completely cured.

ANNA RAU: Tumors in the rest of the mice shrank significantly. The results have been so promising that Dr. Nagarkatti is already beginning clinical trials with leukemia patients.

Dr. Voth believes researchers like Nagarkatti are headed in the right direction.

DR. ERIC VOTH: Let’s keep it in the corridors of science. Let’s keep it in the FDA. Let’s deliver what’s really medicine. That is the individual cannabinoids.

ANNA RAU: But this epilepsy sufferer says patients cannot afford to wait on science.

MEDICAL MARIJUANA USER: I don’t know how long it’s going to be before they really find out exactly what is working for me and for others.

ANNA RAU: Medical marijuana remains legal in Montana, for now. In April, lawmakers passed a full repeal of the law, but Gov. Brian Schweitzer vetoed it.

JEFFREY BROWN: Anna Rau’s one-hour documentary, “Clearing the Smoke: The Science of Cannabis,” is airing on many public television stations this summer.

You can also watch it online. You will find a link to Montana PBS on our website, NewsHour.PBS.org.

SUPPORT YOUR PBS LOCAL STATION

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Israeli nursing home prescribes medical marijuana

The Hadarim Geriatric Home in Israel has been prescribing medical marijuana to some residents with treatment-resistant conditions.

“What does it do? It makes me tranquil and less uptight. I’m able to take it easy, and I feel restful. Before that my hands were in pain, like someone suffering from Parkinson’s disease,” said one elderly man who was prescribed marijuana said. “It stopped after three months. My hands don’t shake anymore, and it’s totally different.”

The Israeli Ministry of Health has allowed the limited use of marijuana since 2008.

Watch video, courtesy of NTDTV, below:

If you or someone you know, is suffering and would like to learn more about using marijuana as medicine, please visit http://www.TheCannabisDoctors.com or call Roger A. Barnes, MD at 626-344-7596.

If you are an administrator in an adult health care facility and would like to learn more about the State of California Department of Social Services Approved Continuing Education Class “California’s Medical Marijuana Program as It Relates to the Adult Residential Facility (ARF) Access under Title 22 Regulations”, please visit http://www.mccdirectory.org/medical_cannabis_training.lasso?-token.classid=128

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Doctors, Patients Assess Effectiveness of Medical Marijuana

Watch the full episode. See more PBS NewsHour.

Transcript

JEFFREY BROWN: And finally tonight: the benefits and limitations of medical marijuana treatments.

Sixteen states have passed laws that allow patients to use the drug to treat side effects of various illnesses. But now some are moving to either limit or repeal those laws. One of them is Montana.

Special correspondent Anna Rau of Montana PBS recently produced a documentary examining the experiences of patients and doctors. This excerpt focuses primarily on what scientists are learning about marijuana’s therapeutic effects.

MEDICAL MARIJUANA USER: I used to be on approximately 14 different prescriptions, and I would still have up to 12 seizures a day. I used to have to take two handfuls of pills. No more.

ANNA RAU, Montana PBS: While this 27-year-old epilepsy patient in Montana is relieved to be taking medical marijuana…

WOMAN: I’m not using it to get any psychological effects off of it. I’m just eating the butter raw with bread.

ANNA RAU: … she’s considerably more anxious about showing her face, and has requested we conceal her identity.

Why do you not want to show your face?

MEDICAL MARIJUANA USER: I am not comfortable showing my face because of all of discrimination that has already happened.

ANNA RAU: She says both she and her husband have lost jobs when she spoke openly about using marijuana to treat her seizures.

Medical marijuana use has been legal in Montana since 2004, when voters there approved an initiative allowing doctors to recommend it to their patients. However, the federal government still classifies the plant as a schedule one drug. That makes it illegal for doctors to prescribe it, and it means state law doesn’t protect patients from federal arrest and prosecution.

MEDICAL MARIJUANA USER: But the fact of the matter is, somebody has to speak up, or nobody will hear these stories.

ANNA RAU: She told us her story in her artist’s studio. Here, she creates much happier works than she did even a few years ago, when her self-portraits plainly showed the toll epilepsy had taken since she was diagnosed at 15.

MEDICAL MARIJUANA USER: I have taken pretty much every anti-epileptic on the market, and some with a little bit more success than others.

ANNA RAU: None of them stopped her seizures, and, by her early 20s, the epilepsy had also spawned depression, anxiety and insomnia. She had to withdraw from college just a few credits short of a fine arts degree. Unable to hold a job, she was bed-bound for years while the epilepsy ruled her life.

MEDICAL MARIJUANA USER: It’s not a life, to live like that.

ANNA RAU: Then she remembered reading stories about the potential of cannabis to treat epileptic seizures, and she desperately wanted to try it, but her home state doesn’t have a medical marijuana law.

MEDICAL MARIJUANA USER: So, I did what I could do. I moved to a state where I could treat it myself.

ANNA RAU: Medical marijuana critic Dr. Eric Voth says the problem is, patients are treating themselves with a plant that’s voter-approved, not FDA-approved.

DR. ERIC VOTH, Institute on Global Drug Policy: So much of the medical excuse movement has come through ballot initiatives and legislative initiatives. And that’s not the way we bring medicines to market. We bring them to market through the FDA and a very careful process of proving safety and efficacy.

ANNA RAU: Dr. Voth is an addiction and pain specialist in Kansas, and he’s also the chairman of the Institute on Global Drug Policy. He says scientific research is the only legitimate route to understanding marijuana’s medical potential, not a hodgepodge of state laws and anecdotal stories.

He says, when patients smoke or ingest marijuana, they are getting a complex and largely unresearched mix of chemicals known as cannabinoids.

DR. ERIC VOTH: If we’re delivering THC, which is the major active ingredient, shouldn’t we be delivering that alone or other cannabinoids alone? But, in fact, what we’re doing is we’re delivering not only one, but 66 cannabinoids. On top of that, were delivering hundreds of contaminants.

ANNA RAU: This epilepsy patient says she’s willing to take the risk, because something in that cornucopia of substances has changed her life.

How did that impact your seizures?

MEDICAL MARIJUANA USER: They started slowing down. I had to build it up in my system. And it wasn’t until I started ingesting it that they really stopped completely.

DR. ERIC VOTH: I’m very suspicious about it because for someone to have been on 14 medications and not solve her problem, and then have this miraculous benefit from one medicine, I just find that suspect.

ANNA RAU: But the potential of marijuana to mitigate epileptic seizures has been recognized by the U.S. Institute of Medicine. The institute has released two reports on the therapeutic potential of cannabis.

The first report, from 1982, found “substantial evidence from animal studies to indicate that cannabinoids are effective in blocking seizures.” Scientists who wrote the 1999 report also found marijuana had anti-seizure effects, but doubted it could be developed into a pharmaceutical-grade epilepsy drug.

However, both reports detailed the promising ability of cannabis to treat pain and disease differently than conventional pharmaceuticals. That’s exactly what scientists at the California Center for Medicinal Cannabis Research found during several placebo-controlled clinical trials.

Dr. Igor Grant is the center’s director, and he says marijuana is not just an anti-nausea drug.

DR. IGOR GRANT, University of California, San Diego: I can say that the cannabinoids are almost certain to be useful in pain, based on the research that we have done, and probably have a place in muscle spasm.

DR. DONALD ABRAMS, University of California, San Francisco: Marijuana contains anti-inflammatory, anti-oxidant and probably anti-cancer compounds in it.

ANNA RAU: Dr. Donald Abrams is an oncology physician who conducted some of the center’s clinical research. He agrees the cannabis plant is a complex mix of substances, but he believes this is a medical benefit, not a detriment.

DR. DONALD ABRAMS: I’m a cancer doctor, and I often suggest to my patients that they consider marijuana for their loss of appetite, nausea, pain, depression and insomnia. It’s one medicine they could use, instead of five.

ANNA RAU: Critics like Dr. Voth are especially skeptical of these kinds of claims. How is it possible that one plant has the potential to impact so many different ailments?

Intriguing answers started appearing in the early ’90s, when researchers pinpointed receptors in the brain and the body that bind with cannabis. Receptors can be described as locks on the surface of a cell, and when the correct key binds with the correct lock, or receptor, it opens the door and delivers messages. Sometimes, the messages are urgent, for example, that the body is feeling pain, or that there’s an invader and the immune system must attack.

Researchers believe cannabinoids can turn down those messages, helping to temper chronic pain and autoimmune disorders. These special receptors are extremely abundant in the brain, but they are also found all over the body and in the major organs, the heart, the liver, kidneys and pancreas.

After finding all these locks that accepted the cannabis key, researchers made the next big discovery: The human body makes its own cannabinoids.

DR. DONALD ABRAMS: We have these circulating chemicals that we produce ourselves that really are very, very similar to the chemicals in the marijuana plant.

DR. PRAKASH NAGARKATTI, University of South Carolina: The only difference is that the cannabinoids that we produce are in such small quantities, and they’re also rapidly degraded, so that, therefore, we are not high all the time.

ANNA RAU: Dr. Prakash Nagarkatti is a professor of pathology and microbiology at the University of South Carolina. He’s one of many scientists in a race to unlock the mysteries of the receptors by using newly created synthetic drugs, instead of tightly restricted whole cannabis.

These synthetics have made research much easier and potentially lucrative. The U.S. patent database shows numerous large pharmaceutical companies have filed recent patents, claiming their cannabinoid receptor drug has the potential to treat almost everything: multiple sclerosis, Alzheimer’s, Parkinson’s, rheumatoid arthritis, Tourette’s, epilepsy, heart disease, obesity, various mental illnesses and the Holy Grail of medicine, a cancer cure.

Dr. Nagarkatti and his team of researchers were one of the first labs to prove a cannabinoid key can seek out a cancerous cell in the immune system, unlock the receptor, and direct the cancer cell to self-destruct.

DR. PRAKASH NAGARKATTI: So, basically, telling the cells basically to commit suicide.

ANNA RAU: Dr. Nagarkatti’s experimental drug was able to eradicate almost 100 percent of the cancer in test tubes. And when they moved on to live mice:

DR. PRAKASH NAGARKATTI: To our surprise, we found that almost 25 to 30 percent of the mice completely rejected the tumor. They were completely cured.

ANNA RAU: Tumors in the rest of the mice shrank significantly. The results have been so promising that Dr. Nagarkatti is already beginning clinical trials with leukemia patients.

Dr. Voth believes researchers like Nagarkatti are headed in the right direction.

DR. ERIC VOTH: Let’s keep it in the corridors of science. Let’s keep it in the FDA. Let’s deliver what’s really medicine. That is the individual cannabinoids.

ANNA RAU: But this epilepsy sufferer says patients cannot afford to wait on science.

MEDICAL MARIJUANA USER: I don’t know how long it’s going to be before they really find out exactly what is working for me and for others.

ANNA RAU: Medical marijuana remains legal in Montana, for now. In April, lawmakers passed a full repeal of the law, but Gov. Brian Schweitzer vetoed it.

JEFFREY BROWN: Anna Rau’s one-hour documentary, “Clearing the Smoke: The Science of Cannabis,” is airing on many public television stations this summer.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Marijuana Slims? Why Pot Smokers Are Less Obese

Main short-term somatic (bodily) effects of ca...

Image via Wikipedia

By Thursday, September 8, 2011 www.time.com

If cannabis causes the munchies, how is it possible that pot smokers are thinner than nonsmokers?

A new study published in the American Journal of Epidemiology finds an intriguing connection between marijuana use and body weight, showing that rates of obesity are lower by roughly a third in people who smoke pot at least three times a week, compared with those who don’t use marijuana at all.

Researchers analyzed data from two large national surveys of the American population, which together included some 52,000 participants. In the first survey, they found that 22% of those who did not smoke marijuana were obese, compared with just 14% of the regular marijuana smokers. The second survey found that 25% of nonsmokers were obese, compared with 17% of regular cannabis users.

The association between pot smoking and lower risk of obesity remained strong even after adjusting for other factors that could influence body fat and health, such as cigarette smoking, age and gender. But the correlation between weed and weight doesn’t mean that marijuana smoking actually causes weight loss.

MORE: Cheers, Ladies! A Drink a Day May Mean Good Health in Older Age

Many other factors could account for the connection. For example, some research finds that highly religious people are less likely to take drugs, but more likely to be obese — perhaps because they’re substituting one compulsive behavior (overeating) for the other (smoking marijuana). So, some of the obese people in the national surveys may be religious folk, who might otherwise be heavy marijuana smokers, but are eating too much instead. That could make it look like marijuana is slimming.

Also consider that one of the most popular uses of medical marijuana is to stimulate appetite in people with cancer, AIDS or other diseases. Such patients are significantly less likely to be obese than the general population — so in this case, weight loss would precede or prompt the marijuana smoking.

Whatever the explanation for the link between marijuana and less obesity, it’s unlikely that cannabis could serve as an effective diet aid. For one, smoking pot has been shown to increase appetite in multiple studies, at least in the short-term, so it likely wouldn’t help dieters resist temptation.

Secondly, a drug that has the opposite effect of THC, marijuana’s main psychoactive ingredient, has itself been shown to aid dieting. Called rimonabant, at high doses the drug nearly tripled the weight loss achieved by people taking placebo. It also frequently caused severe depression and suicidal thoughts, however, so while it was briefly approved by European authorities, it was ultimately pulled from the market.

MORE: Reverse Engineering the Marijuana ‘Munchies’: What Causes Binge Eating?

Of course, none of this explains why marijuana smokers in the national survey samples didn’t get fatter by taking a drug that can clearly stimulate appetite. One factor may be tolerance: many of marijuana’s effects are reduced in frequent users, as the body adjusts to it.

Another may be substitution — the smokers could be seeking comfort by smoking more marijuana, rather than eating more. Or, perhaps other ingredients in cannabis like cannabidiol (CBD) could reduce the appetite-increasing effects of THC in the same way that they reduce its paranoia-inducing properties.

Whatever the case, marijuana research never lacks for surprises!

Find this article at:

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Reverse Engineering the Marijuana ‘Munchies’: What Causes Binge Eating?

SAN FRANCISCO - MARCH 31:  Pistachios sit on a...

Image by Getty Images via @daylife

The “munchies” may be triggered not only by marijuana hitting the brain, but also by its effects on the gut, according to new research that suggests intriguing possibilities for the development of new drugs to fight obesity.

It turns out that, biologically, the effect of marijuana on the gut mirrors that of eating fatty foods. Studying the digestive tract of rats, researchers led by Daniele Piomelli, professor of pharmacology at the University of California, Irvine, teased out why that first bite of fatty food spurs increased craving.

The taste of fatty food hitting the tongue sets off a cascade of cellular effects. Initially, it sends a message to the brain. The brain then sends a message to the gut, where intestinal receptors are stimulated to produce endocannabinoids. In turn, these chemicals affect hunger and satiety and ramp up your appetite for even more fat-laden foods. That’s why you can’t eat just one French fry.

The intestinal receptors, known as CB1 receptors, are the same type of receptors that interact in the brain with THC, the main active ingredient in cannabis. That helps explain why marijuana notoriously triggers the “munchies:” a desire to eat high-fat or sweet foods. But, until now, scientists had thought all the action was in the brain.

Piomelli’s group designed a clever experiment in rats to study where the munchies arose. The rats were given various liquid diets: a health shake, a sugar solution, a protein-heavy liquid and high-fat drink made with corn oil. The food was surgically prevented from staying in the rats’ stomachs; it was drained through a tube before it could reach the intestines. That allowed the researchers to figure out whether the signal to keep eating came from the brain based on the taste of fatty foods on the tongue, or whether the gut was somehow involved.

Since the food never reached the gut, the researchers expected to find that the signal occurred only in the brain. “We were looking everywhere and we were sure that somewhere in the brain CB1 would be activated,” says Piomelli. “Very much to our surprise, we saw nothing of the sort.”

Fortunately, after the feeding experiment, researchers had saved frozen organ tissues from the rats. By going back and examining them, they discovered that fatty food activated CB1 receptors in part of the upper intestine, the jejunum. Further investigation revealed that this occurs because tasting fat triggers the brain to want more — and this signals the gut to increase activity at CB1 receptors, making craving stronger.

The intestinal area affected was not a surprise. “The gut’s got a brain of own and that’s one of the very important regions,” says Piomelli. Indeed, the gut has more nerves than any other area of the body outside the brain (and even more of the mood-associated neurotransmitter serotonin than the brain does).

Piomelli notes that evolutionarily speaking, it would make sense for animals to gorge on as much fat as possible. You never know whether famine is around the corner. But the researchers were also surprised to find that it was only fat — not the sugar- or protein-laden liquids — that activated gut CB1 receptors. “Sugar and protein had no effect,” Piomelli says, noting that there must be other mechanisms aside from CB1 involved in the appetite pathway, because smoking marijuana can also produce sugar cravings.

The researchers found that when they blocked CB1 receptors with a drug, rats lost interest in eating additional fat (but not other types of food). If a drug could be developed to mimic that effect — to reduce the cravings spurred by having a single potato chip — it could be enormously helpful in fighting obesity and binge eating.

In fact, one such drug, rimonabant (Acomplia), which blocks CB1 receptors in both the brain and body, made it to market in Europe as an effective obesity fighter. But it was not approved by the U.S. Food and Drug Administration. Ultimately, due to safety concerns over increased risk of anxiety, depression and even suicide, it was pulled in Europe.

“Rimonabant … induced bad side effects like suicidal thoughts due to its activity [in the brain],” says Jonathan Farrimond, a researcher at the University of Reading who studies cannabinoids and feeding and was not associated with the study. So to avoid side effects, a new drug would have to block gut receptors without affecting the brain.

In Piomelli’s study, the researchers used just such an experimental drug, which blocks CB1 but does not cross the blood-brain barrier. Unfortunately, this chemical has toxic metabolites that prevents it from being used in humans. Still, the research supports the idea that a safer CB1-blocking compound is possible.

“Our research suggests that one can target binge eating with a peripheral CB1 antagonist,” says Piomelli. He says people might one day avoid or reduce obesity with a “pill to take when one has the urge to splurge on high-fat foods like French fries, potato chips or ice cream.”

Since Piomelli’s research was done only on rats and looked only at short-term feeding, rather than weight gain over time, much more work is required before a new drug could be developed. The study was published in the Proceedings of the National Academy of Sciences.

If you or someone you know is suffering from a medical condition and want to learn more about using marijuana as medicine, please call Dr. Roger A. Barnes at 626-344-7596 or visit www.TheCannabisDoctors.com to schedule a confidential medical marijuana evaluation.

 

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Marijuana use up, meth use down, says study of illegal drugs

Various prescription and street drugs may caus...

Image via Wikipedia

(CBS) How’s the war on drugs going? A new government survey on illegal drugs says pot use is up but use of methamphetamine and cocaine is trending downward.

The National Survey on Drug Use and Health found that pot use rose among Americans aged 12 and older from 5.8 percent in 2007 to 6.9 percent in 2010. That’s 17.4 million American teens and adults.

The survey, conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), also showed methamphetamine user rates have plummeted by nearly half, from 731,000 users in 2006 to 353,000 in 2010. Cocaine use also dropped from 2.4 million users in 2006 to 1.5 million in 2010.

Overall, however, illicit drug use is slightly up, from 8.7 percent of the population in 2009 to 8.9 percent in 2010.

“We stand at a crossroads in our nation’s efforts to prevent substance abuse and addiction,” SAMHSA Administrator Pamela S. Hyde, said in a written statement. “This nation cannot afford to risk losing more individuals, families and communities to illicit drugs or from other types of substance abuse.”

If some drug rates are down, why are more Americans smoking pot?

“Emerging research reveals potential links between state laws permitting access to smoked medical marijuana and higher rates of marijuana use,” Gil Kerlikowske, director of National Drug Control Policy, said in a written statement. ” I urge every family – but particularly those in states targeted by pro-drug political campaigns – to redouble their efforts to shield young people from serious harm by educating them about the real health and safety consequences caused by illegal drug use.”

The complete survey results can be found here.

This article originally available at http://www.cbsnews.com/8301-504763_162-20103881-10391704.html

If you or someone you know is suffering from a chronic condition, including substance addiction, please call us at 626-344-7596 to learn more about using marijuana as a medicine. You can also visit our website at www.TheCannabisDoctors.com

 


Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Compound in Marijuana Prevents Chemotherapy Side Effect

Various prescription and street drugs may caus...

Image via Wikipedia

Researchers at the Temple University School of Pharmacy reported that nerve pain that results as a side effect of the chemotherapeutic agent paclitaxel can be prevented by cannabidiol, a compound in the marijuana plant.

Cannabidiol (CBD) is the second most commonly occurring compound in the cannabinoid family (the group of medicinal compounds in the cannabis plant). Cannabidiol has many proven medical benefits, including anti-inflammatory, anti-anxiety, anti-convulsant, and anti-psychotic properties. It also has been shown to reduce muscle spasms, promotes sleep and helps to relieve pain. It is non-psychoactive, that is, it does not contribute to the “high” that one experiences with the use of cannabis that is due to the compound THC.

In a recent study published in the July issue of the journal Anesthesia and Analgesia, investigators studied the effect that CBD had on a particularly difficult side effect of the chemotherapeutic agent paclitaxel (brand name Taxol or Abraxane). Paclitaxel is used to treat patients with lung cancer, ovarian cancer, breast cancer, head and neck cancer and advanced forms of Kaposi’s sarcoma. A common side effect of paclitaxel (in up to two-thirds of patients receiving it) is peripheral neuropathy, damage to the nerves in the body that causes pain, numbness, tingling, sensitivity to touch and/or muscle weakness. Often when this side effect occurs, paclitaxel doses must be lowered or it must be stopped altogether, interfering with the cancer treatment.

In this study, it was shown that female mice (who appeared to be more sensitive to this side effect than male mice) who received treatment with cannabidiol did not develop paclitaxel-induced nerve pain. Let’s hope that this research continues and that CBD can be tested in humans. It is amazing that a well-known side effect can be PREVENTED (not just treated after it happens!) with a natural medicine in marijuana. All of those opposed to marijuana and marijuana research need to open their eyes to the SCIENCE of cannabis!

CBD is currently studied in labs all over the world, as it is recognized as a medicinal compound with tremendous potential. Unfortunately, much of the cannabis that is available for medical marijuana patients in legal states is low in its content of CBD. As more people become aware of the medicinal properties of CBD, plants with higher CBD content will hopefully be more available.

Study citation: Ward SJ, Ramirez MD, Neelakantan H, et al. Cannabidiol Prevents the Development of Cold and Mechanical Allodynia in Paclitaxel-Treated Female C57Bl6 Mice. Anesth Analg 2011 Jul 7.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Medical Marijuana: Pros and Cons

According to the National Institute of Health, when medical marijuana is consumed properly, patients could find relief from a number of medical conditions:

  1. Marijuana is an excellent analgesia for chronic pain due to a variety of conditions.
  2. It controls nausea and vomiting associated with cancer chemotherapy.
  3. It helps with neuralgic and movement disorders, such as muscle spasticity and seizures.
  4. Bon appètit! Marijuana stimulates appetite and relieves Cachexia (the physical wasting away of AIDS and cancer sufferers).
  5. The drug decreases intraocular pressure inside the eyeball for relief of glaucoma.
  6. Marijuana has sedative effects to reduce anxiety and depression.

 

Adverse Effects

All medicines, regardless of how effective they may be, will have some side effects. Marijuana is no exception. It releases chemicals in the nervous system that causes patients to temporarily experience impairment of motor skills, slower reaction time and physical coordination which may last for hours after consumption. In addition, patients should not drive, operate heavy machinery or engage in any activity which requires alertness while using medical cannabis.

When marijuana is inhaled, patients might experience Tachycardia (faster heart beat) and heart palpitations.  The chemicals in marijuana, THC and other cannabinoids, may cause blood vessels to dilate and can cause problems for those with cardiovascular disease. Conversely, marijuana may also cause blood pressure to drop and create dizziness for some people.

Long Term Effects

Although some researchers have shown that there are minimal long-term effects with marijuana usage, continual use of the drug may cause some mood disturbances, depression, and apathy, even in apparently healthy individuals. For those reasons, it is highly recommended for patients to have an intermission with the drug for at least 3 weeks every 3-4 months. The purpose of the intermission is to assist patients to distinguish side effects of marijuana from possible symptoms of any underlying illness.

Patients may experience possible withdrawal syndrome associated with discontinuance of marijuana use after as little as a week. Withdrawal syndrome, nonetheless, is uncommon and is not found in the majority of users. Furthermore, the body does not become physically dependent on marijuana. Signs showing possible withdrawal syndrome are mood swings, insomnia, irritability, and mild depression. The apathy associated with marijuana use could contribute to other conditions such as social isolation, generalized anxiety disorder, and obesity.

To learn more about becoming a legal medical marijuana patient, please visit http://www.thecannabisdoctors.com or call us at 626-344-7596 to schedule a confidential evaluation.

Tags: , , , ,